Cancer Treatment Results  Survival Rates Cancer Treatments / Therapy Results
Cancer
 

Click here to go back to your search results.

Melanoma treatment details. Biologic therapy. Immunotherapy. Dana-Farber Cancer Institute, Boston, MA, United States



Survival: 17.5 months
   
Toxicity Grade: 5
   
Treatments: Biologic therapy
Immunotherapy
   
Drugs:
Country: United States
   
City/State/Province: Boston, MA
   
Hospital: Dana-Farber Cancer Institute
   
Journal: Link
   
Date: 11/2014

Description:
Patients:
This phase 2 study involved metastatic melanoma patients who were divided into two separate treatment groups. Group A consisted of 123 patients with a median age of 61 years; 69.1% were male. Group B had 122 patients with a median age of 64 years; 63.9% were male.

Treatment:
Patients in group A received biologic therapy with ipilimumab (a monoclonal antibody that blocks the CTLA-4 protein) and immunotherapy with sargramostim (GM-CSF), which stimulates the immune system.

Patients in group B received biologic therapy with ipilimumab alone.

Toxicities:
There were two treatment-related deaths in group A due to cardiac arrest and colon perforation.

There were seven treatment-related deaths in group B due to colon failure, multiorgan failure, respiratory failure, and kidney failure.

Results:
The median overall survival for groups A and B were 17.5 and 12.7 months, respectively.

Support:
This study was partially supported by Bristol-Myers Squibb and Genzyme.

Correspondence: Dr. F. Stephen Hodi; email: stephen_hodi@dfci.harvard.edu

E-mail to a Friend Email Physician More Information